Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild
cognitive impairment may be due to loss of glutamate receptors in the aging brain. There is
evidence CX516 enhances brain activity by specifically targeting remaining glutamate
receptors in the affected portions of the brain. This study will test the safety and efficacy
of CX516 in the symptomatic treatment of participants with mild cognitive impairment.